Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
about
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsBariatric surgery for non-alcoholic steatohepatitis in obese patientsNon-alcoholic fatty liver disease: what the clinician needs to know.Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicMetabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential linkNonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and managementTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDThe therapy of insulin resistance in other diseases besides type 2 diabetesNon-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatmentTreatment of nonalcoholic steatohepatitis in adults: present and futureDiagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of EndocrinologyNonalcoholic fatty liver disease: new treatmentsCellular and molecular mechanisms in the pathogenesis of liver fibrosis: An updateEfficacy of Berberine in Patients with Non-Alcoholic Fatty Liver DiseaseHepatic steatosis and Type 2 diabetes: current and future treatment considerations.Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysisLiraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trialComparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.NAFLD and liver transplantation: Current burden and expected challenges.The current role of thiazolidinediones in diabetes management.Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.Controversies in the Diagnosis and Management of NAFLD and NASH.Evolving therapies for liver fibrosis.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.Pathogenesis of non-alcoholic fatty liver disease.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseFXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Modern approach to the clinical management of non-alcoholic fatty liver diseaseMolecular pathways in non-alcoholic fatty liver disease.Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
P2860
Q22299426-FCA8F2BC-B339-45B2-8080-2FD599249B95Q24240455-B6891B32-F461-4871-8829-BA75DB72843DQ24563068-F6015FB2-3C54-49C4-B2AC-D26488E5E8EEQ24563381-9E288B50-D183-4658-AC6E-FB9057A059E0Q24631619-70B0872E-8561-4FDD-97D0-7AF59EFD9607Q24649618-BF93CDB7-4A49-4BFE-AD9B-B06D0B2FC905Q26751258-C7FDDCAD-7963-4475-960D-C855D10D7DD6Q26752487-580BFDE3-0C02-42C0-97FB-46655FD2F0CFQ26822399-9FEB6625-F399-4C49-B9DB-7A0AF61381E8Q26829503-B24A2568-8B90-42FA-9A1E-E8D3ED1C4683Q26852019-D62E6D0F-0ED1-4077-A2B0-04253C55C276Q26852403-0CAAFD25-0DEF-4258-B64F-8F6654365952Q26998471-8C45DE82-9495-4ED9-9DC1-10A767E79CA1Q27021161-072A88B9-68A7-462F-9927-B6D3E5BF9A44Q27027703-DAAC6872-EB83-4795-ABC7-DE34463921A9Q27301440-235AC1DE-AB2D-43BD-8105-0FD9BE790F8CQ27691399-070D1427-26FF-45C3-84A4-5198268307CAQ28477748-C6300B66-53ED-4084-B234-8E9D42D08413Q28661700-767E4E95-65BE-4FB5-9C69-4668604DB695Q30248535-7D67E85E-42EB-4246-B99C-23BD2FB9052EQ30248646-90D99D9E-B6A6-4566-B652-A88325D66C0DQ30250347-113A467A-611D-4512-B160-D5FF7C0D3421Q30401022-227BA226-E17A-4CEE-8BB5-89CDDBF8D812Q30412296-E0692BF7-787B-42FD-AC3B-6879822B0BA7Q30539166-6DF6EF43-7E85-4B77-9B7E-F745BCDA0F98Q30577903-DE516143-8518-407A-A139-8C860E6EE729Q33563333-1B1CAB22-99C9-4AA5-92B7-F344093738A5Q33574413-73E0F957-7359-4537-BDFB-C52A5B430B9CQ33606303-DA2B985A-B45B-4817-80FF-9A6112EDCA5CQ33607697-7B65AF08-6BBA-471D-AC89-AC43BA946306Q33741191-D24AFCAF-30D5-47A4-8C8D-FDCDE84404D5Q33755829-77FE4FBD-11C8-43D6-8158-9A6F76562011Q33802278-CBFEAEA6-DF3E-44D2-BE0C-7998C0ABCF94Q33880303-588DC0B5-9B73-40C8-85F3-8522C4C698CBQ33886923-F2B6E0BE-BB31-4FB8-BEE9-B53DCBCDAA45Q33890230-AE390612-BEF8-4E4A-BED6-766186F8A7F9Q33891750-DB1EDBC5-BAB4-4004-9CFA-F356F98666B1Q34166119-F7E830EA-1659-4E03-B23F-766D9C25B68CQ34168532-1DDA8232-DCF6-4CC6-81FB-6410AF3EB99DQ34297858-35859202-1938-4497-AB06-34FFF9C76480
P2860
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@en
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@nl
type
label
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@en
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@nl
prefLabel
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@en
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@nl
P2093
P50
P1433
P1476
Randomized, placebo-controlled ...... nonalcoholic steatohepatitis.
@en
P2093
Adam Lawson
Andrew S Austin
Jan G Freeman
Jonathan Webber
Linda Morgan
Philip V Kaye
Stephen D Ryder
P304
P356
10.1053/J.GASTRO.2008.06.047
P407
P577
2008-06-25T00:00:00Z